Catalog No.
RHN02601
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Applications
ELISA
Target
EGF-like protein 6, Epidermal growth factor-like protein 6, MAEG, MAM and EGF domains-containing gene protein, EGFL6
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8IUX8
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1861
Note
For research use only.
Tumor vascular proteins as biomarkers in ovarian cancer., PMID:17327606
EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells., PMID:27803106
EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis., PMID:30455428
Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation., PMID:30951671
miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis., PMID:32393810
The emerging role of EGFL6 in angiogenesis and tumor progression., PMID:32624687
Knockout of EGFL6 by CRISPR/Cas9 Mediated Inhibition of Tumor Angiogenesis in Ovarian Cancer., PMID:32983976
EGFL6 promotes colorectal cancer cell growth and mobility and the anti-cancer property of anti-EGFL6 antibody., PMID:33726836
Epidermal growth factor-like domain protein 6 recombinant protein facilitates osteogenic differentiation in adipose stem cells via bone morphogenetic protein 2/recombinant mothers against decapentaplegic homolog 4 signaling pathway., PMID:35220882
Race-associated molecular changes in gynecologic malignancies., PMID:35992327
Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics., PMID:36239936
Antibody therapeutics for epithelial ovarian cancer., PMID:36302510
Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy., PMID:36804621
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer., PMID:36930815
Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer., PMID:37023452
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors., PMID:37311055
Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas., PMID:37326992
Low-grade serous ovarian cancer: expert consensus report on the state of the science., PMID:37591609
Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins., PMID:37909041
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer., PMID:38009662
The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients., PMID:38081436
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition., PMID:38118413
Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis., PMID:38471508
Angiogenesis-Enabled Human Ovarian Tumor Microenvironment-Chip Evaluates Pathophysiology of Platelets in Microcirculation., PMID:38553940
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study., PMID:38776484
Targeting ONECUT2 inhibits tumor angiogenesis via down-regulating ZKSCAN3/VEGFA., PMID:38797268
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14., PMID:39265466
Egfl6 promotes ovarian cancer progression by enhancing the immunosuppressive functions of tumor-associated myeloid cells., PMID:39312740
UBA1 inhibition sensitizes cancer cells to PARP inhibitors., PMID:39626673
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer., PMID:39787747
For research use only. Not for human or drug use.
